Table 3.
<2 Years (n = 11) |
2–4 Years (n = 18) |
>4 Years (n = 7) |
ap Value | |
---|---|---|---|---|
Gender, n (%) | 0.182 | |||
Female | 7 (63.6) | 14 (77.8) | 7 (100) | |
Male | 4 (36.4) | 4 (22.2) | 0 (0) | |
Age (year) ± SE (range) | 59.5 ± 2.1 (48–77) | 57.8 ± 2.8 (34–75) | 62.3 ± 1.3 (56–66) | 0.454 |
BH (cm) ± SE (range) | 157.1 ± 1.5 (148–165) | 159.4 ± 1.6 (150–174) | 153.6 ± 1.0 (150–157) | 0.810 |
BW (kg) ± SE (range) | 63.0 ± 2.8 (45–75) | 64.7 ± 3.1 (46–93) | 56.6 ± 4.0 (45–76) | 0.936 |
DM (%) | 1 (9.1) | 8 (44.4) | 1 (14.3) | 0.104 |
Hypertension (%) | 2 (18.2) | 6 (33.3) | 0 (0) | 0.216 |
Lesion site, n (%) | 0.903 | |||
Left | 4 (36.4) | 9 (50.0) | 3 (42.9) | |
Right | 7 (63.6) | 9 (50.0) | 4 (57.1) | |
Duration (month) ± SE (range) | 10.4 ± 4.3 (1–48) | 12.7 ± 2.9 (2–38) | 28.6 ± 5.6 (12–48) | 0.016 |
Classification (%) | 0.113 | |||
Persistent | 7 (63.6) | 14 (77.8) | 2 (28.6) | |
Recurrence | 4 (36.4) | 4 (22.2) | 5 (71.4) | |
CSA (mm2) (SE) | 14.0 ± 1.1 | 15.1 ± 1.4 | 11.6 ± 1.0 | 0.414 |
No. of injection (SE) | 3.7 ± 0.5 | 3.1 ± 0.5 | 2.3 ± 0.6 | 0.206 |
Outcome | 0.077 | |||
Effective | 4 (36.4) | 14 (77.8) | 4 (57.1) | |
Poor | 7 (63.6) | 4 (22.2) | 3 (42.9) | |
Other treatment, (%) | 2 (18.2) | 7 (38.9) | 2 (28.6) | 0.640 |
Follow-up period (months) (SE) (range) | 14.6 ± 2.1 (6–23) | 35.1 ± 2.0 (25–47) | 56.7 ± 2.6 (50–67) | <0.001 |
BH = Body height; BW = Body weight; DM = Diabetes mellitus; CSA = Cross-sectional area; SE = standard error. a Kruskal–Wallis test, Fisher’s Exact Test.